{"analyses":[{"ciLowerLimit":".02","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":".28","estimateComment":"Response of PR or better","groupDescription":"Phase I part of this phase I/II study","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"response rate of PR or better","paramValue":"0.10","testedNonInferiority":false},{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.47","estimateComment":"Response of PR or better","groupDescription":"Phase II part of this phase I/II study.","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"response rate of PR or better","paramValue":"0.33","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"28","value":"10"},{"groupId":"OG001","lowerLimit":"21","upperLimit":"47","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Response rate of PR or better to the combination treatment of CCI-779 (Temsirolimus) and bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma","dispersionType":"90% Confidence Interval","groups":[{"description":"Response of PR or better per the Blade criteria in phase I part of this phase I/II study of CCI779 and velcade","id":"OG000","title":"CCI779 Response Phase I"},{"description":"Response of PR or better per the Blade criteria in phase II part of this phase I/II study of CCI779 and velcade","id":"OG001","title":"CCI779 Response Phase II"}],"paramType":"NUMBER","populationDescription":"All patients included in analysis","reportingStatus":"POSTED","timeFrame":"10 months","title":"Best Response to Combination Treatment","type":"PRIMARY","unitOfMeasure":"percentage of patients"}